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Running title: Inducing labour in hypertension: Foley catheter vs. oral misoprostol 
 
BSTRACT  
OBJECTIVE    To determine the effectiveness and economic impact of two methods for induction of 
labour in hypertensive women, in low-resource settings. 
 
DESIGN   Cost-consequence analysis of a previously reported multi-centre, parallel, open-label 
randomized trial. 
 
SETTING & POPULATION   602 women with a live fetus, aged>18 years requiring delivery for pre-
eclampsia or hypertension, in two public hospitals in Nagpur, India. 
 
METHODS   We performed a formal economic evaluation alongside the INFORM clinical trial. 
Women were randomised to receive transcervical Foley catheterisation or oral misoprostol 25mcg. 
Healthcare expenditure was calculated using a provider-side micro-costing approach. 
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MAIN OUTCOME MEASURES   Rates of vaginal delivery within 24hours of induction, healthcare-
expenditure per completed treatment episode. 
 
RESULTS   Induction with oral misoprostol resulted in lower healthcare expenditure, mean difference 
(-)$20.6USD [95%CI ((-)$12.73USD-(-)26.74USD)], and improved achievement of vaginal delivery 
within 24hours of induction, mean difference 10% [95%CI (-2%-17.9%), p=0.016)]. Oxytocin 
administration time was reduced by 135.3minutes [95%CI (84.4–186.2mins), p<0.01), and Caesarean 
sections by 9.1% [95%CI (1.1%-17%), p=0.025)] for those receiving oral misoprostol. Following 
probabilistic sensitivity analysis, oral misoprostol was cost saving in 63% of 5,000 bootstrap 
replications and achieved superior rates of delivery within 24 hours of induction, vaginal delivery, and 
vaginal delivery within 24 hours of induction in 90.7%, 98.7% and 99.4% of bootstrap simulations.  
Based on univariate threshold analysis, the unit price of oral misoprostol 25mcg could feasibly 
increase 31-fold from $0.24 to $7.50 per 25mcg tablet and remain cost saving. 
 
CONCLUSION  Compared to Foley catheterisation for the induction of high-risk hypertensive 
women, oral misoprostol improves rates of vaginal delivery within 24h of induction and may also 
reduce costs. Additional research performed in other low-resource settings is required to determine 
their relative cost-effectiveness. 
 
FUNDING  Funded by a grant to the University of Liverpool from the DFID/MRC/Wellcome Trust 
through the Joint Global Health Trials Scheme (ref G1100686/1).  
 
KEYWORDS  Cost-consequence, Economics, Hypertension, Low-resource settings, Preeclampsia, 
Labour Induction 
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CLINICAL TRIALS.GOV IDENTIFIER NCT01801410, URL: 
https://clinicaltrials.gov/ct2/show/NCT01801410 
 
TWEETABLE ABSTRACT  
Oral misoprostol less costly & more effective than Foley catheter for labour induction in 
hypertension 
 
INTRODUCTION 
Hypertensive disorders, including preeclampsia, are the most common medical complication of 
pregnancy, accounting for ~14% of the estimated 303,000 global annual maternal deaths.
1,2 
A great 
deal of this burden is experienced in developing countries, where the incidence of pre-eclampsia is 
increased considerably.
3,4 
 
Timely delivery, preferably by vaginal route, remains the only definitive cure for preeclampsia, and is 
therefore vital to achieve favourable maternal and neonatal outcomes.  Hence, the induction of labour 
is a critical intervention in the management of hypertension in pregnancy. Two low-cost methods, low 
dose oral misoprostol and the Foley balloon catheter, have been previously recommended for the 
induction of labour within low resource settings, but are yet to be directly compared.
5
  
 
The prostaglandin E1 analogue oral misoprostol is a highly effective induction agent,
6
 however it 
carries a uterine hyperstimulation rate of 5-10%,
7
 potentially resulting in hypoxic damage to the fetus. 
Although evidence from low-resource settings is scant, studies conducted in developed health 
economies suggest Foley balloon catheterisation may be equally effective as oral misoprostol for the 
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induction of labour, with lower rates of uterine hyperstimulation,
8-10
 but also a slower speed of 
induction and increased requirement for caesarean section.
8
 Induction with the Foley balloon catheter 
may therefore result in a reduction of risk to the fetus, but with the caveat of a slower labour and an 
increased use of oxytocin.  Because in many low-resource settings, oxytocin is administered under 
gravity alone (using drip counters), it is possible that any neonatal benefits from Foley balloon 
induction may be outweighed by the complications of over dosage with oxytocin.  
 
To date, the sum of available evidence suggests both methods are promising, however the relative 
cost-effectiveness of these methods for induction of labour in women with gestational hypertension 
remains unknown in low-resource settings.  We conducted a cost-consequence analysis of a 
previously reported multicentre randomized controlled trial (RCT),
11
 comparing oral misoprostol with 
Foley balloon induction in women with gestational hypertension, to compare the respective efficacy, 
healthcare resource utilisation and adverse event profile of these therapeutic indications for the 
induction of labour among those with gestational hypertension in a low-resource setting. 
 
MATERIALS & METHODS 
Study design & Participants 
We undertook a cost-consequence analysis of a previously reported multi-centre, parallel, open-label 
randomized trial at two public hospitals in Nagpur, India, between December 2013 and June 2015.  
The study was approved by the Research Ethics Committees at Government Medical College, and the 
University of Liverpool.  As required by the Drug Controller General of India, women provided both 
written and video-recorded oral consent. The trial is registered with the clinical trials registry 
ClinicalTrials.gov: NCT01801410.   
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The trial protocol is published elsewhere.
12
 In short, however, women requiring delivery for 
hypertension or preeclampsia were randomised to either cervical ripening with transcervical Foley 
catheter or 25mcg oral misoprostol tablets given every 2 hours.  Only women >18 years of age with 
ongoing pregnancies and a live fetus, in whom the decision had been made to induce vaginal delivery 
because of preeclampsia or hypertension, were eligible to participate.  Women unable to give 
informed consent, those with a prior caesarean delivery, multiple pregnancy, ruptured membranes, 
clinically diagnosed chorioamnionitis or a history of allergy to misoprostol, were ineligible for the 
trial.   
 
Randomisation and masking 
Women were informed about the study by their doctor when the need for induction of labour 
occurred, and enrolled by research staff on the labour ward on the day of induction.  After informed 
consent, a sequentially numbered, sealed, opaque envelope containing the participant’s group 
assignment in a 1:1 ratio was opened by research staff.  The randomisation was stratified by centre 
and used randomly assigned block sizes of 4, 6 and 8.  Due to differences in administrative method 
between the two interventions, the masking of intervention allocation would have been very difficult 
and was therefore not done.  
 
Procedures/Interventions 
Prior to randomisation, the resident doctor performed a digital examination, to establish a baseline 
Bishop score and cervical dilation.  Women randomised to the Foley catheter arm underwent 
induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon).  The catheter 
remained in place until it was expelled when active labour started, or alternatively, until 12 hours had 
elapsed, in which case an artificial rupture of membranes (ARM) was performed, and an oxytocin 
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infusion commenced.  Similarly, if the Foley catheter fell out within 12h, the membranes were 
ruptured and an oxytocin infusion commenced.  
 
Women assigned to the misoprostol group were induced using oral misoprostol tablets (Cipla 
Misoprost 25mcg), every 2 hours for a maximum of 12 doses (24 hours) or until active labour 
commenced.  In primigravida women, if contractions had not commenced after 2 doses, the dosage 
could be increased to 50mcg every 2 hours.  Once in labour (defined as regular painful contractions 
with a cervical dilation of at least 4cm), no more misoprostol was used and artificial membrane 
rupture and/or oxytocin infusion was used as clinically indicated.   In both arms, if labour had not 
commenced after 24 hours, the case was considered a ‘failed induction’ and the decision on further 
management was made by the clinical team.   
 
For women in both groups, oxytocin was administered with a regular drip infusion set, monitored by 
counting the number of drops per minute. One unit of oxytocin was injected into 500ml of Ringer’s 
lactate, started at a rate of 2mU/minute (15 drops/minute), and increased every 30 minutes by 
2mU/min until there were three-four contractions in ten minutes.  All women were monitored by the 
research staff on a one-to-one basis. Participants with severe hypertension received magnesium 
sulphate and anti-hypertensives both before and after randomisation as per the hospital protocol.  
 
Outcomes 
The primary clinical outcome of the clinical trial was the achievement of vaginal delivery within 24 
hours of induction. As such, our cost-consequence analysis considered the comparative achievement 
of vaginal delivery, delivery (by any method) within 24hours of induction, and a composite measure 
of vaginal delivery within 24hours of commencing induction. We also report the comparative ‘costs 
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per successful vaginal delivery within 24hours of induction’, from the perspective of the Indian 
healthcare system. Although the study was neither designed nor statistically powered for sub-group 
analyses, exploratory subgroup analyses were used to highlight potentially important differences in 
the cost-effectiveness of the two-treatments, which could be attributed to differences in observable 
patient characteristics.   
 
Healthcare expenditure was estimated by multiplying the observed utilisation of healthcare resources, 
as recorded at the patient’s bedside by trial administrators; by associated unit costs obtained from the 
finance department of Government Medical College, Nagpur, India. Because unit costs were obtained 
in Indian Rupees (INR) for the financial year of 2014/2015, costs were inflated using the consumer 
price index, and then converted into US Dollars (USD) using a purchasing power parity adjusted 
exchange rate of 17.22INR to 1USD as estimated by the World Bank.
13
 Because data were non-
normally distributed, 95% confidence intervals for treatment costs were imputed using 5,000 non-
parametric gamma bootstrap simulations, followed by the percentile method to define lower and 
upper confidence limits. Sampling distributions were derived from the observed mean and standard 
deviation of each cost component (delivery, induction, inpatient, neonatal), for each treatment group.  
All unit costs are reported in Table S1.  We additionally assessed the acceptability of each induction 
method by asking participants about (1) self-reported pain experienced, (2) acceptability with the 
amount of time taken, and (3), whether participants would use the same method for induction again?  
 
Statistical analysis  
We used summary statistics to describe the characteristics of the trial groups at baseline. Categorical 
variables were summarised by frequency and percentage, while continuous variables were reported as 
mean and standard deviation (SD). We analysed data for the primary economic outcome from a 
modiﬁed intention-to-treat (ITT) perspective, including all randomly assigned participants, except for 
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those in whom primary outcome data were missing, due to withdrawal from the trial post-
randomisation. Normally distributed continuous variables were compared using the Student t-test.  
 
The sample size was estimated a-priori, assuming a vaginal delivery rate of 41% with the Foley 
catheter, based on previously published data using identical induction protocols and outcomes to this 
study.
14-16
 Full details of the sample size calculation, in addition to data concerning the occurrence of 
adverse events, which bore no clear and translatable cost to the healthcare providers, (e.g. headache, 
maternal vomiting, and meconium-stained liquor), are reported elsewhere.
11
 
 
Table S1: Unit costs of healthcare resource utilisation 
 
Role of the funding source 
The trial was funded by a grant to the University of Liverpool from the DFID/MRC/Wellcome Trust 
through the Joint Global Health Trials Scheme (ref G1100686/1).   
 
RESULTS 
Supplementary Figure 1: CONSORT Flow chart for the study 
Table 1: Baseline characteristics of study groups 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Recruitment & Clinical efficacy  
Between December 2013 and June 2015, 2,412 women were assessed for eligibility, with 602 women 
included in the trial (Supplementary Figure 1). For a single patient, primary outcome data were 
missing for the primary outcome, and for this reason this patient was excluded from the analysis, 
resulting in a total of 601 participants in a modified intention-to-treat analysis. Baseline characteristics 
were similar for the two groups, as shown within Table 1.  
 
Those receiving oral misoprostol 25mcg demonstrated greater achievement of the primary clinical 
outcome of the trial; with 57% [95%CI (51.4-62.5%)], as opposed to 47% [95%CI (41.5-52.8%)] in 
the Foley group achieving a vaginal delivery within 24 hours of induction (p=0.0162).  Vaginal 
delivery was observed in 59.3% and 49.8% of misoprostol and Foley patients respectively 
(p=0.0210), while 92.5% of misoprostol and 89.3% of Foley patients delivered within 24 hours of 
induction (p=0.1913). 
 
Determinants of costs, and treatment acceptability 
Misoprostol patients incurred a mean treatment cost of $117.5 during their hospital episode, [95%CI 
$111.06-$123.45], a 14.9%, or $20.6 reduction when compared to those receiving Foley 
catheterisation, at $138.1 per patient [95%CI $127.06–$146.28, p<0.0001). Those randomised to the 
Foley group incurred a mean induction cost of $26.4 per patient [95%CI ($8.92-$50.91)], compared to 
$15.7 per patient [95%CI ($1.26-$39.67)] in those receiving oral misoprostol.  Most of this difference 
was attributable to a significantly higher utilisation of oxytocin in the Foley group, (81.6% vs. 52%), 
an increased duration of oxytocin administration (5.9 vs 2.5 hours per patient, (p<0.0001)), and an 
increased use of artificial rupture of membranes (77.2% vs. 60.7%, p=0.001).  
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Delivery-related healthcare expenditure was reduced, on average, by $2.3 (95% CI $1.34–$3.79) per 
patient in those receiving oral misoprostol. This saving was attributable, in the majority, to the 
significant reduction in caesarean section rate (50.3 vs. 41.1%, p=0.025), and spinal anaesthesia (50% 
vs. 41.1%, p=0.0275) for oral misoprostol patients, as demonstrated in Table 2. 
 
Those undergoing Foley catheterisation also exhibited higher inpatient costs than those receiving oral 
misoprostol.  The time between randomisation and commencing induction was almost four times 
greater for Foley patients (0.56 to 0.16 hours, p=0.0004), while the time from induction to delivery 
was reduced by approximately 90 minutes for those receiving oral misoprostol (14.35 vs. 12.85 hours, 
p=0.0094).  Additionally, in the postpartum period, patients receiving oral misoprostol spent an 
average 11.4 hours fewer in hospital prior to discharge (136.96 vs. 125.45 hours, p=0.0792). The costs 
of neonatal care were almost equivalent in both groups, with a $3.3 saving (95%CI (-)$1.06-$7.67) in 
favour of Foley catheterisation. Most women in both groups found their assigned method of 
induction, and the duration of the induction, to be acceptable, and the pain they experienced to be 
either slight or moderate (Table 3). More women in the misoprostol group (82.8%) than the Foley 
catheter group (72%) would use the same method in the future should they require another induction 
(Table 3), p=0.006. 
 
Table 2: Utilisation rates and determinants of cost difference between Foley catheterisation and oral 
Misoprostol 25mcg. 
 
Maternal and neonatal outcomes  
No significant difference in adverse events were observed. Uterine hyperstimulation occurred in 0.3% 
and 0.7% of the Foley and misoprostol groups respectively, (p=0.566). Similarly, rates of fetal heart-
rate abnormality (5.7% vs. 4.0%), severe hypertension (7.0% vs. 7.6%), postpartum haemorrhage 
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(0.7% vs. 0.7%) and use of blood products after trial entry (1.7% vs. 0.3%) were not statistically 
different. Two babies (1%) were stillborn to women induced with the Foley catheter, and nine babies 
(1%) died in total, three in the Foley group (all due to prematurity) and six in the misoprostol group 
(three due to prematurity, one from prematurity plus intrauterine growth restriction, one from 
intrauterine growth restriction alone, and one from asphyxia). The causes of death did not differ 
significantly between the two groups. Neonatal morbidity, as judged by Apgar scores, asphyxiation, 
admission to special care units, ventilation, and oxygen administration rates were similar in both 
groups, further details of the adverse event profile of each treatment are provided in Tables 3 and 4.  
 
Table 3: Maternal outcomes for those receiving Foley catheterisation and oral Misoprostol 25mcg. 
 
Table 4: Neonatal outcomes for those receiving Foley catheterisation and oral Misoprostol 25mcg. 
 
Sensitivity analysis Following probabilistic sensitivity analysis, oral misoprostol was cost saving 
in 63% of 5,000 bootstrap replications. Oral misoprostol also achieved superior rates of delivery 
within 24 hours of induction, vaginal delivery, and vaginal delivery within 24 hours of induction in 
90.7%, 98.7% and 99.4% of bootstrap simulations.  Based on univariate threshold analysis, the unit 
price of oral misoprostol 25mcg could feasibly increase 31-fold from $0.24 to $7.50 per 25mcg tablet, 
and still remain weakly dominant over Foley catheterisation; resulting in equivalent costs and 
improved rates of induction within 24hours of labour.  
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Sub-group analyses 
As expected, healthcare expenditure per completed treatment episode increased with the extent of 
prematurity, as shown within Table S2. Oral misoprostol demonstrated resource savings over Foley 
catheterisation at all gestational ages, in addition to demonstrating improved effectiveness, the extent 
of which increasing with the extent of prematurity. For those with a Bishop’s score of ≥3, oral 
misoprostol resulted in a $15.3 per patient reduction in treatment costs and a 13% improvement in 
vaginal delivery within 24 hours of induction (52% vs. 58.8%, p=0.12). For those with a Bishop’s 
score of <3, almost twice as many women delivered vaginally within 24hours in the oral misoprostol 
cohort (45% vs. 22.7%) (p=0.03), while healthcare expenditure was also reduced by $37.6 per patient.  
 
Table S2: Comparison of healthcare costs for Foley catheterisation and oral Misoprostol 25mcg.  
 
DISCUSSION 
Main findings 
The results of this multicentre randomized trial, performed in two hospitals within the Maharashtra 
province of India, demonstrate that for the induction of hypertensive women in low-resource settings, 
low dose oral misoprostol 25mcg is both more clinically effective, and less resource intensive than 
transcervical Foley catheterisation. 57% [95%CI (51.4-62.5%)], of our oral misoprostol group, as 
opposed to 47% [95%CI (41.5-52.8%)] in the Foley group achieved a vaginal delivery within 24 
hours of induction (p=0.0162), while mean treatment costs equalled $138.10 per patient [95% CI 
$127.06–$146.28] in the Foley group, reducing by 14.9% to $117.51 per patient [95%CI $111.06-
$123.45] in the oral misoprostol group. This $20.6 saving per patient could have provided a 40 hour 
stay in ICU, or 77 hours of oxygen administration in this low-resource setting. Sensitivity analysis 
demonstrated a 63% probability of oral misoprostol being cost saving over Foley catheterisation, and 
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a 90.7%, 98.7%, and 99.4% probability of achieving superior rates of delivery within 24 hours of 
induction, vaginal delivery, and vaginal delivery within 24 hours of induction respectively. 
 
Strengths & limitations 
A key strength of this study is that to the best of our collective knowledge, it is the first-of-its-kind to 
demonstrate the relative cost-effectiveness and budget impact of these two treatments for the 
induction of labour in hypertensive women. Additionally, the study relied upon internally collected 
financial data concerning real world purchasing and reimbursement costs for the hospitals involved, 
while all observations concerning patient-level resource use were collected at the patient’s bedside via 
trial administrators, resulting in considerable precision.   
 
The limitations of this study primarily concern the real-world validity of several assumptions. Firstly, 
outside of trial conditions, it is unclear whether midwives would have the capacity to continuously 
provide oral misoprostol at optimal two-hourly intervals. As such, the efficacy of oral misoprostol 
demonstrated within this trial may be greater than that which we would expect to observe in the real 
world. Secondly, the financial costs of staff time, whether nurse, junior doctor, or consultant, were 
accounted for on an equal basis, due to the unavailability of data concerning individual staff salaries. 
While oral misoprostol can be administered by most staff members, a greater skill level is necessary 
to insert a Foley catheter, suggesting that the costs of Foley insertion were possibly underestimated 
during this analysis. Third, hospitals vary hugely in their approach to intrapartum protocols. The oral 
misoprostol and Foley catheter protocols described in this study are based on previous studies, 
guidelines and expert advice. However, they are not the definitive versions, and the costs (and clinical 
outcomes) could vary considerably with even small variations in indication, oxytocin use or staff 
supervision. Settings both within India and internationally will also vary in their rates of caesarean 
section and costs of neonatal care and these could have marked effects on the cost-effectiveness. The 
results of this study can only therefore be viewed as an indication of what happens with a typical 
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protocol and hospital setting. Of particular note is the absence of intrapartum continuous electronic 
monitoring and electronic oxytocin pumps. This increases its applicability and generalisability to 
other low resource settings without these technologies, but limits its applicability to settings where 
these technologies are more readily available. 
 
Interpretation in light of other evidence 
The induction of labour is a critical intervention in the management of hypertension in pregnancy. 
Two low-cost methods, low dose oral misoprostol and the Foley balloon catheter, have been 
previously recommended for the induction of labour within low resource settings, with both found to 
have advantages over other induction methods in systematic reviews,
6-8,10 
but until recently, had never 
been directly compared.  
 
Due to a lack of effect on uterine contractions during the cervical ripening phase,
8,10
 Foley 
catheterisation has been shown to result in safe but slow labours, which avoid the dangers of 
hyperstimulation, but may result in increased requirement for both caesarean section,
8
 and additional 
need for labour augmentation with oxytocin. This was observed within our study, with 57% of 
misoprostol and 47% of Foley patients achieving a successful induction. As a result, over 80% of our 
Foley cohort required additional uterine stimulation with oxytocin in comparison to just 52% of the 
misoprostol cohort, a finding synonymous with existing literature.
10
 Furthermore, amongst those who 
did require oxytocin infusion, the duration of infusion also increased by 57% for those in the Foley 
group (432.3 vs. 297mins). This resulted in a greater use of limited healthcare resources during the 
induction interval. Furthermore, because in many low-resource settings, oxytocin is administered 
under gravity alone, without the safeguards of electronic infusion control, any reduction in oxytocin 
usage may not only reduce health service costs, but also improve maternal safety; with the risks 
associated with oxytocin over dosage falling. 
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Additionally, given the increased susceptibility for failed inductions, literature collected in western 
settings has demonstrated that Caesarean section rates may be higher in those induced with the Foley 
balloon catheter, when compared to other induction methods,
8, 17
 and the results of this study, 
performed in a low-resource setting, corroborate this finding. Those receiving the Foley catheter 
experienced an 18.1% increase in Caesarean-section rates relative to those receiving oral misoprostol, 
suggesting that not only is the use of Foley catheterisation in this setting likely to result in an 
escalation of risk to patients, given considerations of infection control and the general risks of 
anaesthesia, but also likely to increase pressures on nursing staff, hospital beds, and highly skilled 
theatre technicians, all of which are likely already in both high demand and short supply.  
 
Given the high prevalence of pre-eclampsia,
1,2,18
 in addition to low levels of investment in publicly 
funded healthcare in India (1.3% of GDP),
19, 20 
the discovery that oral misoprostol results in both 
improvements in clinical outcomes, and reductions in healthcare expenditure, is an important finding. 
The $5,611.4222 difference in total healthcare expenditure between the two arms of this trial over the 
study period, could have otherwise provided 89 Caesarean sections, 445 days in a special care baby 
unit, or 3,563 bags of saline solution. As such, the opportunity for similar savings to be achieved on a 
larger scale, which could then be used to promote health where unmet clinical need is greatest, could 
have considerable impact.  
 
Further research should aim to determine whether the results observed in this province of India, are 
generalizable to other provinces or low-resource settings, and whether widening the inclusion criteria 
to better reflect routine clinical practice, including those with a prior C-section, would change the 
study conclusions. There are a wide variety of induction methods available, but this paper relates only 
to these 2 specific methods. For example, some practitioners are using the Foley catheter at the same 
time as low dose misoprostol to improve outcomes, and this also deserves further research. Widening 
the perspective of the analysis beyond solely health-service related outcomes would also provide 
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valuable insights as to the societal impact of each treatment indication, particularly with respect to 
time away from work, impact on ability to perform household duties, and the financial costs of 
birthing partners requiring accommodation for the duration of hospital stay.  
 
CONCLUSION 
The results of this study suggest that when compared to Foley catheterisation for the induction of 
high-risk hypertensive women, oral misoprostol improves rates of vaginal delivery, delivery within 
24h of induction, and vaginal delivery within 24h of induction, and may also reduce costs. Additional 
research performed in other low-resource settings is essential to determine the relative cost-
effectiveness of these two treatments. 
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Table 1: Baseline characteristics of study groups 
Measure  
Foley Catheter 
(n=300) 
Misoprostol 
(n=302) 
Study site         GMC n (%) 150 (50.0) 151 (50.0) 
                           Daga n (%) 150 (50.0) 151 (50.0) 
Background 
Woman’s age mean (s.d.) [range] 24.0 (3.5) [18 - 42] 23.7 (3.1) [18 - 37] 
Mother’s 
education: 
No formal education n (%)   5 (1.7)  2 (0.7) 
Primary n (%)   86 (28.7) 112 (37.1) 
Secondary n (%)   149 (49.7) 131 (43.3) 
University n (%)   60 (20.1) 57 (19.0) 
Medical history 
Nulliparous (no previous pregnancies >28 
weeks) 
 n (%) 247 (82.3) 236 (78.1) 
Previous hypertension in pregnancy:  n (%) 8 (2.7) 16 (5.3) 
Previous stillbirth  n (%) 1 (0.3)  5 (1.7) 
Pre-existing diabetes / renal or liver disease n (%) 0 0 
Pre-existing chronic hypertension n (%) 0     1 (0.3) 
State at recruitment 
Gestational age (best estimate in weeks) mean (s.d.) [range] 38.2 (2.2) [29 - 42] 38.1 (2.1) [29 - 41] 
Estimate made by ultrasound at <20 weeks  n (%) 131 (43.7) 127 (42.1) 
Systolic BP (mm/Hg)  mean (s.d.) [range] 142.2 (11.3) [104-180] 
142.8 (12.5) [102-
190] 
Diastolic BP (mm/Hg)  mean (s.d.) [range]  95.0 (8.3) [60-130] 94.7 (8.3) [66-120] 
Proteinuria at 
enrolment: 
         Nil or trace n (%)  156 (52.0)  162 (53.7) 
          +1 / +2 n (%)  122 (40.6)  121 (40.0) 
          +3 / +4 n (%)  22 (7.4)  19 (6.3) 
Hypertensive symptoms at 
enrolment: 
 n (%)  64 (21.3)  58 (19.2) 
Woman received MgSO4 in last 12 hours    n (%)  45 (15.0)  42 (13.9) 
Woman currently on anti-hypertensives  n (%) 292 (97.3) 289 (95.7) 
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Table 2: Utilisation rates and determinants of cost difference between Foley catheterisation and oral 
Misoprostol 25mcg. 
 Foley 
catheterisation 
(n=299)  
Cost per 
patient ($) 
Oral 
Misoprostol 
(n=302) 
Cost per 
patient ($) 
p-value 
Induction-related determinants of costs 
Anti-hypertensives (mg per person) 
Nifedipine 8.96 $0.08 6.6 $0.06 0.1712 
Aldomet  340.3 $0.28 351.8 $0.29 0.7169 
Labetolol  14.7 $0.15 16.9 $0.17 0.5996 
Antibiotics (mg per person) 
Ciffran IV  4.7 $0.03 0 $0.00 0.0346 
Metrodinazole IV 0 $0.00 2.7 $0.10 0.1576 
Taxim IV 33.4 $0.95 33.1 $0.06 0.9853 
Analgaesics (mg per person) 
Paracetemol  13.4 $0.01 11.6 $0.01 0.7792 
Other 
MgSO4 (gm per person)# 1.74 $1.47 1.69 $1.41 0.8972 
Oxytocin (minutes of infusion 
per person) 
432.3 $9.08 297 $4.12 0.000 
ARM** 193 (77.2%) $8.21 153 (60.7%) $6.38 0.001 
Delivery-related determinants of costs 
Caesarean 150 (50.2%) $15.79 124 (41.1%) $12.93 0.025 
Spinal anaesthesia 149 (49.8%) $15.69 124 (41.1%) $12.93 0.0308 
Local anaesthesia 94 (31.4%) $3.98 114 (37.7%) $4.59 0.1968 
Episiotomy* 96 (64.4%) $4.05 118 (65.9%) $4.88 0.0891 
Inpatient determinants of costs 
Time (hours) from 
randomisation to induction 
0.56 $0.19 0.16 $0.05 0.0001 
Time (hours) from induction to 
delivery 
14.35 $4.90 12.85 $4.38 0.0008 
Time (hours) from delivery to 136.96 $46.74 125.45 $42.81 0.1503 
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discharge 
Total time as inpatient (hours) 151.86 $51.82 
 
138.46 $47.25 0.0432 
Neonatal determinants of costs 
Ventilation (mins) 50.05 $0.44 26.03 $0.23 0.736 
Oxygen administration (mins) 82.35 $0.36 86.62 $0.38 0.4165 
NICU stay (mins) 491.15 $4.35 548.24 $4.80 0.8087 
*Out of 149 vaginal deliveries in Foley group vs. 179 vaginal deliveries in misoprostol group 
** Out of those with rupture time recorded 
# Includes costs of fluids and intracatheters to administer MgSO4 
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Table 3: Maternal outcomes for those receiving Foley catheterisation and oral Misoprostol 25mcg. 
  
Foley Catheter 
(n=300) 
Oral misoprostol 
(n=302) 
Mean difference 
(95% CI) 
p 
value 
Vaginal birth within 24hours 141 (47%) 172 (57%) 10·0% (–2·0 to 17·9) 0.0136 
Delivered within 24hours 268 (89.3%) 279 (92.4%) 3·1% (–1·5 to 7·6) 0.194 
Vaginal birth 149 (49.7%) 178 (58.9%) 9·3% (1·3 to 17·2) 0.0212 
Mode of birth         
Spontaneous vaginal birth 146 (48.7%) 176 (58.3%) 9·6% (1·7 to 17·5) 0.0194 
Forceps or vacuum birth 3 (1%) 2 (0.7%) –0·3% (–1·8 to 1·1) .. 
Caesarean section 151 (50.3%) 124 (41.1%) –9·2% (–17·2 to –1·3) 0.025 
Oxytocin required 244 (81.6%) 157 (52%) 
–29·6% (–36·8 to –
22·5) 
<0.000
1 
Hours of Oxytocin 5.9 2.5 3.4 (2.7 to 4.1) 
<0.000
1 
Total Time spent in hospital  151.6 138.4 13.2 (-2.9 to 29.2) 0.0537 
Randomisation to induction 0.56 0.16 0.4 (0.17 to 0.63) 0.0004 
Induction to delivery 14.3 12.9 1.4 (0.2 to 2.6) 0.0094 
Delivery to discharge 136.8 125.4 11.4 (-4.4 to 27.1) 0.0792 
Analgesia         
Spinal anaesthesia 150 (50%) 124 (41.1%) –8·9% (–16·9 to –1·0) 0.0275 
Local anaesthesia 94 (31.3%) 114 (37.7%) 6·4% ( –1·2 to 14·0) 0.097 
Complications of labour and birth         
Uterine hyperstimulation 1 (0.3%) 2 (0.7%) 0·3% (–0·8 to 1·5) 0.566 
Fetal heart rate abnormality 17 (5.7%) 12 (4%) –1·7% (–5·1 to 1·7) 0.332 
Diagnosis of postpartum 
haemorrhage 2 (0.7%) 2 (0.7%) 0 (–1·3 to 1·3) 0.995 
Blood products after trial entry 5 (1.7%) 1 (1.3%) –1·3% (–2·9 to 0·3) 0.099 
Severe hypertension 21 (7%) 23 (7.6%) 0·6% (–3·5 to 4·8) 0.772 
Any form of complication 44 (14.7%) 37 (12.3%) –2·4% (–7·9 to 3·0) 0.385 
Side-effects during induction         
Mild diarrhoea 2 (0.7%) 7 (2.3%) 1·7% (–0·3 to 3·6) 0.094 
Amount of pain experienced     
None/slight 91 (30.3%) 86 (28.5%)   
Moderate 145 (48.3%) 152 (50.3%)   
High/extreme 64 (21.3%) 64 (21.2%)   
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Acceptability of amount of time 
taken     
Very acceptable   49 (16.4%)   52 (17.2%)   
Acceptable 129 (43.1%) 145 (48.0%)   
Neutral   81 (27.1%)   75 (24.8%)   
Unacceptable   35 (11.7%)   26 (8.6%)   
Very unacceptable     5 (1.7%)     4 (1.3%)   
Would use same method again?         
Yes 216 (72%) 250 (82.8%) … … 
No 59 (19.7%) 35 (11.6%) … 0.006 
No preference 25 (8.3%) 17 (6%) … … 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 4: Neonatal outcomes for those receiving Foley catheterisation and oral Misoprostol 25mcg 
  
Foley Catheter 
(n=300) 
Oral misoprostol 
(n=302) 
Mean difference 
(95% CI) 
p 
value 
Outcome of birth         
Livebirth 298 (99.3%) 302 (100%) 0.70% .. 
Stillbirth 2 (0.7%) 0 .. .. 
Birthweight (g)       0.918 
Mean (SD) 2612 (464) 2616 (490) 4 (–72 to 80) .. 
Median (Range) 
2600 (1000–
3830) 2600 (750–3800) .. .. 
Apgar Score at 1min       0.687 
<7 10 (3.4%) 12 (4%) 0·6% (–2·4 to 3·6) .. 
>7 288 (96.6%) 290 (96%) .. .. 
Apgar Score at 5mins       0.058 
<7 1 (0.3) 6 (2%) 1·7% (–0·1 to 3·4) .. 
>7 297 (99.7%) 296 (98%) .. .. 
Apgar Score at 10mins       0.431 
<7 0 5 (1.7%) 1.70% .. 
>7 298 (100%) 297 (98%) .. .. 
Other neonatal outcomes         
Neonatal death 3 (1%) 6 (2%) 
1·0% (–1·04 to 
2·97) 0.322 
Baby admitted to special 
care nursery 19 (6.4%) 28 (9.3%) 2·9% (–1·4 to 7·2) 0.186 
Baby given oxygen 33 (11.1%) 42 (13.9%) 2·8 (–2·5 to 8·1) 0.293 
Baby ventilated 4 (1.3%) 4 (1.3%) 0 (–1·9 to 1·8) 0.985 
Sarnat score completed 19 (6.3%) 29 (9.6%) 3·3% (–1·0 to 7·6) 0.138 
Normal 13 (68.4%) 20 (69%) .. .. 
Moderate 6 (31.6%) 8 (27.6%) .. .. 
Severe 0 1 (3.4%) .. .. 
 
 
